- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03281382
Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer
PHASE 1 TRIAL OF ONCOLYTIC ADENOVIRUS-MEDIATED CYTOTOXIC AND IL-12 GENE THERAPY IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This protocol proposes a phase 1 trial combining oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy with chemotherapy in metastatic pancreatic cancer. Nine subjects (3 cohorts, 3 subjects/cohort) with metastatic pancreatic cancer will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels (cohort 1- 1 x 1011 vp, cohort 2- 3 x 1011 vp, cohort 3- 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either through the stomach or duodenal wall using endoscopic ultrasound (EUS) guidance. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
The primary endpoint is toxicity at day 21. A secondary endpoint is rates of ≥ grade 3 CTCAE adverse events. Exploratory endpoints include 1) intensity, persistence, and biodistribution of HSV-1 TK gene expression, and 2) association of immunological measurements (i.e., cytokine levels, NK cytolytic activity) with toxicity and clinical outcome.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven (biopsy or cytology) metastatic pancreatic adenocarcinoma.
- Age ≥ 18 years.
- No prior treatment (surgery, chemotherapy, radiotherapy, or biological therapy) for the study cancer.
- Zubrod performance score of 0 - 2 within 30 days of registration.
Subjects must have adequate baseline organ function, as assessed by the following laboratory values, within 30 days before initiating the study therapy:
- Adequate renal function with serum creatinine ≤ 1.8 mg/dL or creatinine clearance ≥ 50 mL/min/m2.
- Absolute neutrophil count > 1,000/μL.
- Hemoglobin > 8.0 g/dL.
- Platelet count > 100,000/μL.
- Bilirubin < 2.0 mg/dL.
- SGOT and SGPT < 3.0 times upper limit of normal (ULN). Subjects with liver metastases may have SGOT/SGPT < 5.0 times ULN.
- Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout and for 60 days beyond the treatment phase of the study.
- Subjects on oral warfarin anticoagulation therapy may be included in this study, but must have close monitoring of their coagulation parameters as altered parameters and/or bleeding have been reported in patients taking Xeloda® and such agents concomitantly. Subjects on other forms of anti-coagulation therapies may need close clinical monitoring for signs or symptoms of bleeding.
- The subject must possess the ability to give informed consent and express a willingness to meet all of the expected requirements of the protocol for the duration of the study.
Exclusion Criteria:
- Pregnant and lactating women.
- Clinical or laboratory evidence of pancreatitis, based on discretion of treating physician.
- Serious non-malignant disease (e.g., congestive heart failure or uncontrolled infections), which, in the opinion of the investigator would compromise study objectives.
- Major surgery planned within 3 months of registration other than diagnostic procedures such as laparoscopy or endoscopic ultrasound and stenting or PEG/PEJ placement.
- Islet cell tumor, benign cyst, peri-ampullary carcinoma or any non-adenocarcinomas.
- Acute infection. Acute infection is defined by any viral, bacterial, or fungal infection that has required specific therapy within 72 hours of initiation of the study therapy (defined as day 1).
- Previous history of liver disease including hepatitis.
- Positive serologic test for Hepatitis B or C at baseline.
- Immunosuppressive therapy including systemic corticosteroids. Use of inhaled and topical corticosteroids is permitted.
- Impaired immunity or susceptibility to serious viral infections.
- Allergy to any product used on the protocol.
- Serious medical or psychiatric illness or concomitant medication, which, in the judgment of the investigator, might interfere with the subject's ability to respond to or tolerate the treatment or complete the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational Arm
Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels.
Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy.
Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician.
On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
|
Oncolytic adenovirus expressing two suicide genes and human IL-12
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity of the gene therapy
Time Frame: 21 days
|
grade 1 - 5 CTCAE adverse events
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
>= grade 3 adverse events
Time Frame: 21 days
|
grade 3 - 5 CTCAE adverse events
|
21 days
|
PET imaging
Time Frame: 14 days
|
HSV-1 TK gene expression via [18F]-FHBG administration and PET imaging
|
14 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11260
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
University Hospital HeidelbergGerman Cancer Research CenterCompletedColorectal Cancer Metastatic | Pancreatic Cancer MetastaticGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
HonorHealth Research InstituteUniversity of Arizona; Agenus Inc.; Translational Genomics Research InstituteNot yet recruitingPancreatic Cancer Metastatic | Pancreatic Adenocarcinoma MetastaticUnited States
-
Pancreatic Cancer Action NetworkActive, not recruitingMetastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Joachim Aerts, MD PhDCompletedMetastatic Pancreatic CancerNetherlands
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
Clinical Trials on Ad5-yCD/mutTKSR39rep-hIL12
-
Henry Ford Health SystemActive, not recruitingProstate CancerUnited States
-
Seoul National University HospitalNewGenPharm Inc.CompletedPancreatic CancerKorea, Republic of
-
Henry Ford Health SystemRecruitingGlioma | Glioblastoma | Astrocytoma | Malignant Glioma of Brain | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Malignant AstrocytomaUnited States
-
Benjamin Movsas, M.D.WithdrawnNon-small Cell Lung Cancer Stage IUnited States
-
Henry Ford Health SystemCompleted
-
Henry Ford Health SystemTerminatedPancreatic CancerUnited States